erlotinib hydrochloride has been researched along with Adenocarcinoma of Lung in 197 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 163 (82.74) | 24.3611 |
| 2020's | 34 (17.26) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, S; Li, K; Li, X; Peng, ZY; Ren, H; Sun, X; Tang, SC; Wang, QS; Wang, R; Xiao, GD; Zhang, J | 1 |
| Chang, HC; Chang, YP; Huang, KT; Lai, CH; Lin, MC; Tseng, CC; Wang, CC | 1 |
| Haga, Y; Hanamuro, S; Higashisaka, K; Izusawa, K; Konishi, H; Lin, Y; Nagano, K; Tsujino, H; Tsutsumi, Y; Yang, L | 1 |
| Belani, CP; Holguin, RAP; Ma, PC; Reed, MF; Schaefer, E; Shen, C; Zhou, S | 1 |
| Chang, JS; Hsieh, KP; Huang, YB; Lee, CH; Shen, MC; Tsai, MJ; Yang, YH | 1 |
| Besiroglu, M; Ozturk, A; Seker, M; Topcu, A; Turk, HM; Yasin, AI; Yurtsever, I | 1 |
| Abe, S; Kusaba, Y; Naka, G; Takeda, Y; Tsukada, A | 1 |
| Bi, L; Chen, HZ; Dong, JK; Gu, WM; Lei, HM; Liang, Q; Luo, MY; Ma, P; Shen, NX; Shen, Y; Tang, YB; Wang, C; Xu, L; Zhou, Y; Zhu, L; Zhuang, G; Zou, JH | 1 |
| Chen, H; Fang, S; Hu, Z; Li, N; Liu, K; Pan, Q; Wei, Y; Xu, G; Xu, S; Zhu, L; Zhu, Y | 1 |
| Li, S; Li, Z; Liu, S; Wang, Z; Zhao, F | 1 |
| Chang, CJ; Chen, CB; Chen, MJ; Chen, WT; Chung, WH; Fang, YF; Hsu, PC; Hui, RC; Hung, SI; Ko, HW; Ko, YS; Li, SH; Lu, CW; Lu, KL; Lu, LY; Pang, JS; Shih, FY; Tseng, LC; Wang, CL; Wang, CW; Wu, CE | 1 |
| Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T | 1 |
| Chen, HZ; Gong, M; Jiang, LL; Lei, HM; Liang, Q; Luo, MY; Shen, NX; Shen, Y; Wang, C; Xu, L; Zhang, KR; Zhang, MC; Zhang, R; Zhou, L; Zhu, L; Zhuang, G; Zou, JH | 1 |
| Chomphoo, S; Khawkhiaw, K; Ruangpratyakul, T; Saengboonmee, C; Seubwai, W; Sorin, S; Thithuan, K; Wongkham, S; Zeng, F; Zhou, Y | 1 |
| Pan-Pan, L; Qing, L; Yang, F; Ye, H; Yue-Yun, C; Zhen-Yu, D | 1 |
| Edwards, A; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Lal, R; Lee, SM; Lewanski, C; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Li, G; Sai, B; Tang, J; Wang, F; Wang, L; Xiang, J; Zhang, L; Zhang, X; Zheng, L | 1 |
| Au, KH; Chiu, CH; Enatsu, S; Frimodt-Moller, B; Garon, EB; Imamura, F; Moro-Sibilot, D; Nadal, E; Nakagawa, K; Nishio, M; Novello, S; Park, K; Paz-Ares, L; Ponce Aix, S; Reck, M; Seto, T; Shih, JY; Visseren-Grul, C; Yoh, K; Zimmermann, A | 1 |
| Bolan, PO; Brenan, L; Dusaj, N; Goodale, A; Johannessen, CM; Landau, DA; Piccioni, F; Schiffman, JS; Zviran, A | 1 |
| Chen, HZ; Lei, HM; Lu, LM; Shen, Y; Wang, CH; Wang, Y; Zhang, J; Zhang, KR; Zhu, L; Zhuang, GL | 1 |
| Bai, Y; Gu, X; Liu, X; Zhao, L; Zhou, X | 1 |
| Awan, NU; Goraya, AW; Hanif, A; Khokhar, MA; Nisaa Zia, NU; Qamar, S | 1 |
| Guan, R; Hu, D; Jiang, W; Li, K; Li, Y; Liao, D; Liu, L; Mansfield, AS; Wang, J; Xia, C; Xiao, L; Xiong, Y; Yang, H; Yang, N; Zeng, L; Zhang, Y; Zhou, C | 1 |
| Ahangari, D; Colinet, B; Ngendahayo, P; Roquet-Gravy, PP | 1 |
| Deng, Q; He, D; Wang, F; Xie, Z; Yang, H | 1 |
| Cho, SL; Chuang, CA; Lai, CF; Liao, WY; Lin, WC | 1 |
| Chen, Y; Liu, F; Lu, T; Tang, J | 1 |
| Amos, C; Cheng, C; Schaafsma, E; Weng, YL; Zhao, Y | 1 |
| Ando, M; Gemma, A; Hagiwara, K; Hino, M; Kobayashi, K; Kubota, K; Miyanaga, A; Nishitsuji, M; Noro, R; Seike, M; Shimokawa, T; Usuki, J; Yomota, M | 1 |
| Chen, T; Fang, W; Han, B; Ji, C; Li, R; Xiong, L; Zhao, W | 1 |
| Brat, K; Jakubíková, L; Šťastná, N | 1 |
| Li, CY; Ma, SH | 1 |
| Chen, M; Chen, W; Han, G; Jiang, Y; Mao, S; Shi, N; Yu, W; Zhang, X | 1 |
| Hsu, CK; Lee, CN; Po-Chao Chiu, F | 1 |
| Heo, DS; Im, SW; Jeon, YK; Keam, B; Kim, DW; Kim, M; Kim, S; Kim, TM; Ku, JL; Lee, C | 1 |
| Adli, M; Aliyev, A; Besiroglu, M; Simsek, M; Turk, HM | 1 |
| Ahn, L; Arcila, ME; Hayes, SA; Iqbal, A; Kris, MG; Luo, J; Makhnin, A; Ng, K; Riely, GJ; Tobi, Y; Yu, HA | 1 |
| Akrour, Y; Duchemann, B; Gaudry, S; Gibelin, A; Gonzalez, F; Jaubert, P; Moreau, AS; Oppenheimer, A; Stoclin, A; Tandjaoui-Lambiotte, Y | 1 |
| Chang, GC; Chen, JJW; Chen, KC; Chin, CS; Hsu, KH; Huang, YH; Su, KY; Tseng, JS; Yang, TY; Yu, SL | 1 |
| Awasthi, S; Bansal, M; Belkina, N; Biswas, R; Califano, A; Chaerkady, R; Charles Jacob, HK; Cultraro, CM; Gao, S; Guha, U; Kashyap, MK; Kirkali, G; Maity, T; Marimuthu, A; Pandey, A; Pitts, S; Singh, S; Venugopalan, A; Zhang, X | 1 |
| Alvarez-Argote, J; Dasanu, CA; Lippman, SM; Plaxe, SC | 1 |
| Chen, Y; Deng, H; Lou, W; Wang, J; Wu, T; Zhu, KY | 1 |
| Gu, FF; Hong, XH; Liang, JY; Liu, L; Liu, YY; Tong, F; Zeng, YL; Zhang, K | 1 |
| Archila, P; Arrieta, O; Cardona, AF; Carranza, H; Corrales, L; Cuello, M; Karachaliou, N; Martín, C; Ortiz, C; Otero, J; Pino, LE; Reguart, N; Rojas, L; Rosell, R; Vargas, C; Wills, B; Zapata, MI; Zatarain-Barrón, ZL | 1 |
| Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY | 1 |
| Cho, JH; Jeon, SH; Kim, HJ; Kim, JS; Kwak, SM; Lee, HL; Nam, HS; Ryu, JS | 1 |
| Hayashi, R; Inomata, M; Kambara, K; Kashii, T; Konishi, H; Miwa, T; Okazawa, S; Shimokawa, K; Tanaka, H; Tobe, K; Tokui, K; Yamada, T | 1 |
| Akiyama, N; Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Iwaizumi, M; Karayama, M; Kono, M; Kusama, Y; Nakamura, Y; Suda, T; Suzuki, Y | 1 |
| Asai, K; Hirata, K; Kawaguchi, T; Kimura, T; Kuwae, Y; Matsumoto, Y; Mitsuoka, S; Sawa, K; Suzumura, T; Watanabe, T; Yamamoto, N; Yoshimoto, N; Yoshimura, N | 1 |
| Ali, SM; Carney, BJ; Costa, DB; Gowen, K; Rangachari, D; Schrock, AB; VanderLaan, PA | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Kato, T; Ogura, T; Okudela, K; Sekine, A; Yamakawa, H; Yamanaka, Y | 1 |
| Jiang, SH; Li, YQ; Song, SS; Zhang, XY | 1 |
| Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ | 1 |
| Drpa, G; Kukulj, S; Manojlovic, S; Sreter, KB | 1 |
| Daido, W; Deguchi, N; Fujihara, M; Funaishi, K; Hattori, N; Ishiyama, S; Ohashi, N; Saito, N; Sakano, A; Taniwaki, M; Yamasaki, M | 1 |
| Cai, SL; Chen, WQ; Jin, XT; Kou, GF; Li, HY; Li, P; Liu, G; Wang, Q; Yan, S; Zhang, YJ | 1 |
| Hebisawa, A; Hirose, T; Kitani, M; Kusaka, K; Matsui, H; Miyakawa, K; Ohta, K; Shimada, M; Tamura, A; Yokoyama, A | 1 |
| Chen, HZ; Dong, JK; Lei, HM; Li, WB; Liang, Q; Shen, Y; Tang, YB; Tong, Y; Wang, Y; Zhang, L; Zhang, S; Zhou, Y; Zhu, L; Zhuang, G | 1 |
| Norberg, E; Queiroz, AL; Vakifahmetoglu-Norberg, H | 1 |
| Akiba, J; Azuma, K; Hoshino, T; Ishii, H; Masuda, K; Matsuo, N; Naito, Y; Nakamura, M; Tokito, T; Yamada, K; Yanagida, E | 1 |
| Chang, CL; Chang, JH; Chang, YC; Chow, JM; Hsu, HL; Lin, WC; Wu, ATH; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Demirkazik, A; Gálffy, G; Kudaba, I; Markóczy, Z; Ostoros, G; Pápai-Székely, Z; Purkalne, G; Rásó, E; Sárosi, V; Somfay, A; Turay, ÜY | 1 |
| Masuda, N; Nakahara, Y; Niwa, H; Sasaki, J | 1 |
| Aigner, P; Barbacid, M; Brcic, L; Casanova, E; Dezso, K; Dome, B; Eferl, R; Grabner, B; Győrffy, B; Hidalgo, M; Hruschka, N; Laszlo, V; Lopez-Casas, PP; Mohrherr, J; Moldvay, J; Moll, HP; Moriggl, R; Musteanu, M; Penninger, J; Popper, H; Pranz, K; Schramek, D; Sibilia, M; Stiedl, P; Stoiber, D | 1 |
| Cai, L; Cao, M; Chen, X; Han, B; Hu, J; Lu, H; Meng, Q; Zhang, H; Zhao, Y | 1 |
| Hase, T; Hasegawa, Y; Matsui, A; Morise, M; Omote, N; Sato, M; Shimoyama, Y; Suzuki, K; Tanaka, I | 1 |
| Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Karayama, M; Nakamura, Y; Suda, T; Suzuki, Y; Tsuchiya, K; Yasui, H | 1 |
| Sharp, CN | 1 |
| Archila, P; Arrieta, O; Avila, J; Bravo, M; Cardona, AF; Carranza, H; Castro, CD; Corrales, L; Martín, C; Otero, J; Pino, LE; Reguart, N; Ricaurte, LM; Rodriguez, J; Rojas, L; Rosell, R; Ruiz-Patiño, A; Vargas, C; Wills, B; Zatarain-Barrón, ZL | 1 |
| Kenzaka, T; Miyoshi, K; Nakaji, H | 1 |
| Hove, J; Powell, SF; Wynja, E | 1 |
| Gu, P; Hu, F; Hu, P; Li, C; Nie, W; Shen, Y; Wang, H; Wang, S; Xu, J; Zhang, B; Zhang, X; Zhang, Y | 1 |
| Chen, LY; Chen, ZT; Liao, XY; Sun, JG; Xu, ZH; Zheng, LP | 1 |
| Cao, L; Huang, J; Jiang, Y; Li, N; Xu, B; Zhang, J; Zhao, M | 1 |
| Agazzi, GM; Berruti, A; Bettoni, V; Borghesi, A; Caprioli, A; Farina, D; Ganeshan, B; Maroldi, R; Ravanelli, M; Roca, E; Tononcelli, E | 1 |
| Erikson, AK; Paripati, HR; Sheedy, JT; Shoudis, SN; Sio, TT; Yu, NY | 1 |
| Grimsrud, KW; Mrugala, MM | 1 |
| Chen, Z; Li, F; Sun, J; Wang, J; Wang, X; Xu, Z; Yang, Q; You, Q; Yu, Y; Zheng, L; Zhou, P; Zhu, G; Zhuo, W | 1 |
| Wang, Z; Wu, YL | 1 |
| Germonpré, P; Van den Wyngaert, T | 1 |
| Carnero, A; Enguita, AB; Ferrer, I; Marrugal, Á; Molina-Pinelo, S; Ojeda-Márquez, L; Paz-Ares, L; Ponce-Aix, S; Quintanal-Villalonga, A; Suarez, R; Yagüe, P | 1 |
| Guo, C; Li, R; Wu, K | 1 |
| Fintelmann, F; Geng, C; Grassberger, C; Hata, AN; Kamran, SC; Maruvka, YE; McClatchy, D; Paganetti, H; Piotrowska, Z; Sequist, LV; Willers, H | 1 |
| Ashtekar, K; DeVeaux, M; Gettinger, S; Goldberg, SB; Lemmon, MA; Lu, D; Park, JH; Politi, K; Song, X; Starrett, JH; Stewart, T; Truini, A; Walther, Z; Wurtz, A; Zelterman, D | 1 |
| Cikes, M; Hecimovic, A; Jakopovic, M; Jankovic Makek, M; Samarzija, M; Vukic Dugac, A | 1 |
| Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK | 1 |
| Hayashi, N; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Masuda, N; Nagashima, Y | 1 |
| Chang, CX; Hu, RH; Li, R; Qi, JL; Shi, SB; Tang, XY; Tian, J | 1 |
| Belaid, I; Ben Ayed, F; Debbiche, G; Jlassi, H; Rais, H | 1 |
| Hou, YH; Pan, JB; Zhang, GJ | 1 |
| Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M | 1 |
| Goto, K; Ishii, G; Matsumoto, S; Nagai, K; Niho, S; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Fujii, T; Matsumura, S; Okamoto, T; Shinyama, M; Tanaka, H | 1 |
| Beau-Faller, M; Bièche, I; Blons, H; Bringuier, PP; Cadranel, J; Cayre, A; de Cremoux, P; de Fraipont, F; Denis, MG; Domerg, C; Escande, F; Gajda, D; Legrain, M; Lizard, S; Morin, F; Mosser, J; Nanni-Metellus, I; Olschwang, S; Piard, F; Pignon, JP; Pretet, JL; Richard, N; Rouquette, I; Saulnier, P; Solassol, J; Voegeli, AC; Zalcman, G | 1 |
| Ema, T; Enomoto, Y; Kawano, R | 1 |
| Gu, QH; Hu, CP; Li, YY; Lu, RL; Wu, L; Yang, HP | 1 |
| Liu, XQ; Qiao, TK | 1 |
| Horn, L; Lammers, PE; Lovly, CM | 1 |
| Li, N; Liu, QW; Ou, W; Wang, BX; Wang, SY; Yang, H; Zhang, SL | 1 |
| Bae, MK; Cho, BC; Kang, DR; Kim, EY; Kim, HR; Kim, JH; Kim, MH; Lee, CY; Lee, JS | 1 |
| Ebina, M; Iida, S; Ise, K; Iwabuchi, E; Kondo, T; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nihira, K; Ono, K; Saito, M; Sasano, H; Sato, I; Yamada-Okabe, H | 1 |
| Fukai, T; Hasegawa, T; Hirasawa, Y; Ikeda, S; Kamiya, Y; Kudo, Y; Matsumura, M; Nagata, A; Shiraishi, E | 1 |
| Leighl, NB; Zer, A | 1 |
| Liu, C; Qu, G; Sun, B; Wang, P; Zhang, Z; Zhou, C | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| Chang, J; Hu, A; Luo, Z; Sun, S; Wang, H; Wang, J; Wu, X; Xing, K; Yu, H; Zhao, X; Zhou, X | 1 |
| Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M | 1 |
| Cao, Y; Du, P; Kim, HJ; Lee, HJ; Settleman, J; Zhuang, G | 1 |
| Bosch-Barrera, J; Brunet, J; Izquierdo, A; Lorencio, C; Menéndez, JA; Porta, R; Rosell, R; Sais, E; Sirvent, JM | 1 |
| Dome, B; Francovszky, E; Galffy, G; Hegedus, B; Losonczy, G; Ostoros, G; Sarosi, V; Tolnay, E; Torok, S | 1 |
| Ge, N; Jiao, W; Qiu, T; Shen, Y; Tang, D; Wang, Y; Xuan, Y; Yan, G; Yao, R | 1 |
| Chang, CY; Chang, GC; Chen, CY; Chen, KC; Chen, YM; Hsu, KH; Huang, MS; Su, KY; Tsai, CR; Tsai, MH; Tseng, JS; Wang, CL; Wu, CW; Yang, CT; Yang, TY; Yu, SL | 1 |
| Ahmed, ZA; Moatter, T; Pervez, S; Siddiqui, A | 1 |
| Alifano, M; Damotte, D; Dupouy, S; Fléjou, JF; Forgez, P; Lupo, AM; Mourra, N; Régnard, JF; Takahashi, T; Trédaniel, J; Wu, Z; Younes, M | 1 |
| Ferrer, L; Ferretti, G; Meynet, E; Moro-Sibilot, D; Pirvu, A; Sakhri, L | 1 |
| Byeon, JH; Jung, YH; Kim, HR; Kim, TJ; Lim, JU; Park, CK; Woo, IS | 1 |
| Belkina, N; Biswas, R; Chaerkady, R; Guha, U; Jacob, HK; Kim, MS; Maity, T; Pandey, A; Shaw, PG; Venugopalan, A; Zhang, X | 1 |
| Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H | 1 |
| Arcila, ME; Hellmann, MD; Kris, MG; Reva, B; Rizvi, NA; Rusch, VW; Yu, H | 1 |
| Jonstrup, SP; Lindahl, KH; Loeschke, S; Olsen, KE; Sørensen, FB | 1 |
| Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D | 1 |
| Bantikassegn, A; Fan, PD; Guha, U; Politi, K; Song, X; Threadgill, DW; Varmus, H | 1 |
| Ambrosio, F; Barbato, C; Cartenì, G; Mocerino, C; Otero, M; Riccardi, F; Scagliarini, S; Vitale, MG | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Buk, L; Jakubiak, M; Krawczyk, P; Mańdziuk, S; Milanowski, J; Pankowski, J; Wojas-Krawczyk, K | 1 |
| Chinda, J; Fujino, T; Hasebe, N; Kabara, M; Kuroshima, T; Maruyama, K; Nakagawa, N; Ogawa, Y; Ohsaki, Y; Yamamoto, Y | 1 |
| Bai, C; Huang, Y; Liao, M; Luo, F; Ma, S; Qin, S; Shi, Y; Wang, C; Yu, S; Zhang, L; Zhang, Q; Zhi, X; Zhou, C | 1 |
| Feng, RT; Liu, GJ; Mei, JZ; Zhang, XJ; Zhao, JZ | 1 |
| Chang, CC; Ho, JH; Hsiao, CH; Hsieh, TL; Hsu, WT; Ji, AT; Lee, OK; Tiong, TY | 1 |
| Adler-Reichel, S; Huber, RM; Rogowski, WH; Schremser, K; Stollenwerk, B; Tufman, AL | 1 |
| Arcila, ME; Busby, N; Kris, MG; Ladanyi, M; Nafa, K; Naidoo, J; Riely, GJ; Rodriguez, K; Sima, CS; Yu, HA | 1 |
| Allo, G; Ishizawa, K; John, T; Jurisica, I; Kim, L; Leighl, NB; Li, M; Liu, G; Liu, N; Martin, P; Mascaux, C; Neel, BG; Ng, C; Pham, NA; Pintilie, M; Sakashita, S; Shepherd, FA; Stewart, EL; Sykes, J; Tsao, MS; Waddell, TK; Wang, D; Yanagawa, N; Zhu, CQ | 1 |
| Hartford, A; Ji, Y; Phillips, J; Ramsey, J; Schwartz, J; Verschraegen, C | 1 |
| Kau, HC; Tsai, CC | 1 |
| Ayeni, D; de Stanchina, E; Goldberg, SB; Hyder, F; Meador, CB; Pao, W; Pirazzoli, V; Politi, K; Sanganahalli, BG | 1 |
| Aoyama, H; Fujita, J; Furugen, M; Haranaga, S; Higa, F; Hirai, J; Kinjo, T; Miyagi, K; Saio, M; Tateyama, M; Uechi, K; Yoshimi, N | 1 |
| Liu, YH; Zhu, WL | 1 |
| Gao, H; Li, X; Wang, S; Xu, H; Yang, H | 1 |
| Boyle, T; Chan, D; He, Y; Hirsch, FR; Li, J; Li, X; Ren, S; Rivard, C; Wang, Y; Zhou, C | 1 |
| Friess, T; Kim, L; Li, M; Liu, G; Martin, P; Mascaux, C; Panchal, D; Pham, NA; Sakashita, S; Shepherd, FA; Stewart, E; Sykes, J; Tsao, MS; Wang, D | 1 |
| Aurisicchio, L; Bergantino, F; Cherubini, E; Ciliberto, G; Costantini, S; De Vitis, C; Fenizia, F; Ferrara, FF; Giarnieri, E; Giovagnoli, MR; Lambiase, M; Mancini, R; Mariotta, S; Normanno, N; Noto, A; Ricci, A; Roscilli, G; Torrisi, MR | 1 |
| Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM | 1 |
| Daga, H; Fujimoto, D; Goto, I; Ikeda, N; Imamura, F; Iwamoto, Y; Kaji, R; Kanehara, M; Katakami, N; Morita, S; Murakami, H; Nakagawa, K; Nakanishi, Y; Negoro, S; Nogami, N; Oguri, T; Saka, H; Satouchi, M; Seto, T; Sugawara, S; Urata, Y; Yoshioka, H | 1 |
| Bulat, T; Golić, I; Incerti, S; Keta, O; Korać, A; Petrović, I; Ristić-Fira, A | 1 |
| Amano, S; Aoyama, M; Hino, N; Inoue, S; Miyoshi, T; Mori, R; Sumitomo, H; Wada, D | 1 |
| Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Fröhlich, H; Hülsmann, H; Kuner, R; Praveen, P; Sültmann, H | 1 |
| Cabuk, D; Cicin, I; Cinkaya, A; Erdogan, B; Hacibekiroglu, I; Hacioglu, MB; Karabulut, S; Kodaz, H; Tanriverdi, O; Tozkir, H; Turkmen, E; Uzunoglu, S | 1 |
| Chu, JG; Li, GX; Qian, GQ; Yin, FY | 1 |
| Bae, E; Choi, SE; Lee, H; Lim, EA; Lim, J; Shin, YK | 1 |
| Chen, X; Cultraro, CM; Guha, U; Lee, MJ; Lizak, MJ; Medina-Echeverz, J; Niu, G; Simpson, RM; Tomita, Y; Trepel, JB; Venugopalan, A | 1 |
| Baba, T; Futaki, M; Iwasawa, T; Kato, T; Ogura, T; Sakuranaka, H; Sekine, A; Suido, A | 1 |
| Boudjemaa, A; Caliez, J; Chouaid, C; Jabot, L; Leroy, K; Monnet, I; Pujals, A; Rousseau-Bussac, G | 1 |
| Nakamura, H; Nishimura, T | 1 |
| Alden, RS; Awad, MM; Bahcall, M; Jaklitsch, MT; Jänne, PA; Kim, ND; Kuang, Y; Lydon, CA; Oxnard, GR; Patel, JD; Paweletz, CP; Sacher, AG; Sholl, LM; Sim, T | 1 |
| Ding, LY; Jiang, ZL; Liu, KJ; Wu, HY; Wu, SX | 1 |
| Hayama, M; Hirashima, T; Morishita, N; Nishida, T; Nishihara, T; Okamoto, N; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A | 1 |
| Urata, Y | 1 |
| Chang, CH; Lee, CH; Wang, JY | 1 |
| Ariyasu, R; Horiike, A; Kawashima, Y; Kitazono, S; Koyama, J; Nishikawa, S; Nishio, M; Oguri, T; Ohyanagi, F; Saiki, M; Sonoda, T; Takano, N; Yanagitani, N | 1 |
| Costa, DB; Huberman, MS; Joseph, LJ; Kobayashi, SS; Malcolm, J; Mockus, SM; Rangachari, D; Reddi, HV; Spotlow, V; VanderLaan, PA | 1 |
| Chen, G; Gao, C; Gao, X; Hu, J; Kuan, SF; Liu, G; Stabile, LP; Zhang, DH | 1 |
| Lam, KC; Mok, TS | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, V; Dennetta, D; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Ugolini, M | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Azzoli, CG; Ginsberg, MS; Janjigian, YY; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pereira, LK; Pietanza, MC; Riely, GJ; Rizvi, NA | 1 |
| Asami, K; Atagi, S; Kawaguchi, T; Kawahara, M; Okishio, K | 1 |
| Döme, B; Fehniger, TE; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, A | 1 |
| Bagai, R; Fan, W; Flask, CA; Fu, P; Hafez-Khayyata, S; Halmos, B; Howell, S; Huang, H; Jiang, S; Koon, H; Kresak, A; Ma, PC; Morrison, B; Tang, Z; Vasanji, A; Yin, L | 1 |
| Gu, A; Han, B; Shen, J; Shi, C; Xiong, L | 1 |
| Chanprapaph, K; Pongcharoen, P; Vachiramon, V | 1 |
| Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
| Chin, A; Depinho, RA; Dinulescu, DM; Faça, VM; Gazdar, AF; Goodman, G; Hanash, SM; Kelly-Spratt, K; Kemp, CJ; Kucherlapati, R; Lockwood, WW; Park, KS; Pitteri, SJ; Politi, K; Sage, J; Taguchi, A; Varmus, HE; Wong, CH; Zhang, Q | 1 |
| Guo, H; Kang, Y; Li, Y; Lin, D; Liu, Q; Tian, G; Wan, Y; Yao, Z | 1 |
| Higashino, M; Hiraishi, Y; Hirano, S; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Naka, G; Nakamichi, S; Sugiyama, H; Takeda, Y | 1 |
| Fujiu, K; Kobayashi, N; Miyamoto, H; Suzuki, H | 1 |
| Ashai, A; Avital, I; Hassan, R; Kalra, N; Raffeld, M; Xi, L; Zhang, J | 1 |
| Hansen, KH; Hansen, NC; Hansen, O; Kristiansen, C; Olsen, KE | 1 |
| Hirata, K; Kimura, T; Kudoh, S; Manabe, M; Mitsuoka, S; Takeda, A; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Dittmann, K; Huber, SM; Mayer, C; Misovic, M; Rodemann, HP | 1 |
| Juergens, R; Levine, MN | 1 |
| Capelletti, M; Crawford, J; Edelman, MJ; Gu, L; Jänne, PA; Kratzke, R; Miller, VA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X | 1 |
| Baldotto, CS; da Silveira, JS; de Lima Araújo, LH; Ferreira, CG; Zukin, M | 1 |
| Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N | 1 |
| Albano, T; Arnovitz, P; Burstein, D; Dhawan, NS; Difeo, A; Farrington, C; Galsky, M; Izadmehr, S; Katz, S; Mazhar, S; Melville, H; Narla, G; Ohlmeyer, M; Okrent, R; Politi, K; Rana, H; Sangodkar, J; Singh, VJ; Yuan, E; Zhang, D | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Ohashi, K; Takata, S; Takeda, H; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Cai, DY; Hong, TT; Hua, D; Wu, XH; Zhang, RX | 1 |
| Girard, L; Heymach, JV; Johnson, FM; Lippman, SM; Minna, JD; Peng, S; Saintigny, P; Sen, B; Wistuba, II; Zhang, L | 1 |
| Jin, C; Li, W; Li, Y; Ren, S; Zhang, D; Zhao, Z | 1 |
| Kimura, Y; Morikawa, N; Murakami, K; Nagano, Y; Tabata, T; Yanagisawa, S | 1 |
| Arcila, ME; de Stanchina, E; Janjigian, YY; Kris, MG; Ladanyi, M; Melnick, MA; Miller, VA; Nebhan, CA; Ohashi, K; Pao, W; Pirazzoli, V; Politi, K; Riely, GJ; Song, X; Spitzler, PJ; Takezawa, K | 1 |
| Al-Shahrour, F; Alexander, D; Baran, M; Carretero, J; Difilippantonio, S; El Meskini, R; Guerin, T; Gumprecht, M; Iacovelli, AJ; Kozlov, S; Kulaga, A; Martin, PL; McCann, T; Mena, S; Schlomer, J; Van Dyke, T; Weaver, Z; Wong, KK | 1 |
| Abe, K; Ebina, M; Endo, C; Inoue, A; Kobayashi, M; Kondo, T; Kumamoto, H; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nukiwa, T; Sasano, H; Sato, I; Suzuki, T; Yamada-Okabe, H | 1 |
| Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S | 1 |
6 review(s) available for erlotinib hydrochloride and Adenocarcinoma of Lung
| Article | Year |
|---|---|
T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.
Topics: Adenocarcinoma of Lung; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
[Lung adenocarcinoma with intramedullary spinal cord metastasis: a case report and review of the literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Disease Progression; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Quinazolines; Radiography; Spinal Cord Neoplasms | 2013 |
The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Brain Neoplasms; Chemoradiotherapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genotype; Glutamates; Guanine; Humans; Keratin-7; Lung Neoplasms; Middle Aged; Palliative Care; Pemetrexed; Pleural Effusion, Malignant; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids; Transcription Factors; Treatment Failure | 2014 |
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Targeted therapy: an evolving world of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
19 trial(s) available for erlotinib hydrochloride and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Predictive Value of Tests; Protein Kinase Inhibitors; Proteomics; Survival Rate | 2019 |
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Ramucirumab; Survival Rate | 2019 |
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Pleural Effusion, Malignant; Pleurodesis; Prognosis; Survival Rate | 2020 |
[A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Humans; Lung Neoplasms; Mutation; Neoadjuvant Therapy; Pemetrexed; Protein Kinase Inhibitors | 2018 |
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Feasibility Studies; Female; Follow-Up Studies; Genetic Testing; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Treatment Outcome; White People | 2018 |
Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pemetrexed; Platinum; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2019 |
Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Treatment Outcome | 2013 |
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antimetabolites, Antineoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Glutamates; Guanine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2014 |
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome | 2014 |
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Thymidine Phosphorylase; Treatment Outcome | 2015 |
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; International Cooperation; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult | 2016 |
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Sex Factors; Smoking; Tumor Stem Cell Assay | 2010 |
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2011 |
[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2011 |
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Smoking | 2012 |
172 other study(ies) available for erlotinib hydrochloride and Adenocarcinoma of Lung
| Article | Year |
|---|---|
M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way.
Topics: Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Membrane Glycoproteins; Methyltransferases; Mice; Mice, Nude; Nerve Tissue Proteins; Receptors, Notch; RNA, Long Noncoding; Signal Transduction | 2021 |
Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Drug Therapy; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies | 2021 |
Progesterone receptor membrane component 2 expression leads to erlotinib resistance in lung adenocarcinoma cells.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Receptors, Progesterone; Signal Transduction | 2021 |
Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Medicare; Mutation; Protein Kinase Inhibitors; United States | 2022 |
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines | 2022 |
The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Sarcopenia | 2022 |
Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Reactive Oxygen Species; Transaminases | 2022 |
Bioinformatics algorithm for lung adenocarcinoma based on macropinocytosis-related long noncoding RNAs as a reliable indicator for predicting survival outcomes and selecting suitable anti-tumor drugs.
Topics: Adenocarcinoma of Lung; Algorithms; Antineoplastic Agents; Computational Biology; CTLA-4 Antigen; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Prognosis; RNA, Long Noncoding | 2022 |
Identifying a lactic acid metabolism-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Etoposide; Gefitinib; Humans; Immunologic Factors; Immunotherapy; Lactic Acid; Lung Neoplasms; Prognosis; Reproducibility of Results; Tumor Microenvironment | 2022 |
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Animals; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Rats; Retrospective Studies; Tyrosine Kinase Inhibitors; Zinc | 2023 |
A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-6; Janus Kinase 2; Lung Neoplasms; Mutation; Phosphoglycerate Mutase; Protein Kinase Inhibitors; Signal Transduction | 2023 |
High glucose enhances the aggressiveness of lung adenocarcinoma via activating epidermal growth factor receptor/signal transducer and activator of transcription 3 pathways.
Topics: Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Humans; Hyperglycemia; Lung Neoplasms; Mice; STAT3 Transcription Factor | 2023 |
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2019 |
BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Marrow; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Insulin-Like Growth Factor Binding Protein 2; Leptin; Lung Neoplasms; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Receptor, IGF Type 1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genetic Fitness; Genotype; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation | 2020 |
Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas.
Topics: Adenocarcinoma of Lung; Aldehyde Dehydrogenase 1 Family; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Metabolic Networks and Pathways; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Reactive Oxygen Species; Retinal Dehydrogenase | 2019 |
Complete remission of membranous nephropathy in a patient with lung adenocarcinoma treated with erlotinib.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Follow-Up Studies; Glomerulonephritis, Membranous; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome | 2020 |
Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation- positive adenocarcinoma lung.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pakistan; Progression-Free Survival | 2019 |
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
Topics: Adenocarcinoma of Lung; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Young Adult | 2020 |
[A case of Sweet syndrome in a patient receiving erlotinib for lung adenocarcinoma].
Topics: Adenocarcinoma of Lung; Dermis; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neutrophil Infiltration; Protein Kinase Inhibitors; Sweet Syndrome; Time Factors | 2020 |
A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Young Adult | 2020 |
Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Erlotinib Hydrochloride; Glucocorticoids; Humans; Kidney; Kidney Function Tests; Lung Neoplasms; Male; Nephritis, Interstitial; Prednisolone; Recovery of Function; Withholding Treatment | 2020 |
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Calpain; Case-Control Studies; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proto-Oncogene Proteins c-met; Survival Rate; Tumor Cells, Cultured | 2020 |
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemotherapy, Adjuvant; Datasets as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Liver Neoplasms; Logistic Models; Lung Neoplasms; Models, Genetic; Molecular Targeted Therapy; Mutation; Predictive Value of Tests; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; RNA-Seq; Signal Transduction; Sorafenib; Transcriptome | 2020 |
Feasibility of Surgical Resection After Induction Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for N2 Lung Adenocarcinomas.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Remission Induction | 2021 |
Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Bevacizumab; Carboplatin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Salvage Therapy | 2020 |
Necrolytic migratory erythema-like eruption associated with erlotinib in a patient with lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Necrolytic Migratory Erythema; Necrosis | 2020 |
Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Survival Analysis | 2020 |
Cutaneous cytomegalovirus (CMV) infection in a patient with metastasized lung cancer.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Cytomegalovirus Infections; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male | 2021 |
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Successful retreatment with erlotinib after erlotinib-related interstitial lung disease.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Remission Induction; Retreatment | 2021 |
Erlotinib and Trametinib in Patients With
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones | 2021 |
Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intensive Care Units; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Noninvasive Ventilation; Oxygen Inhalation Therapy; Protein Kinase Inhibitors; Respiration, Artificial; Respiratory Insufficiency; Retrospective Studies; Survival Rate | 2022 |
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Isotope Labeling; Lung Neoplasms; Mass Spectrometry; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proteomics; Quinazolines; Reproducibility of Results; Signal Transduction; Tyrosine | 2017 |
Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Nail Diseases; Protein Kinase Inhibitors; Thumb | 2018 |
Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Diosgenin; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-6; Lung Neoplasms; Melanthiaceae; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Rhizome; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel | 2017 |
Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Hispanic or Latino; Humans; Lung Neoplasms; Male; Middle Aged; Mutation | 2017 |
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Basal Cell; Disseminated Intravascular Coagulation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Quinazolines; Treatment Outcome | 2017 |
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Duodenal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Pyrimidines; Quinazolines; Treatment Outcome | 2017 |
Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.
Topics: Acrylamides; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors | 2017 |
De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2017 |
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged, 80 and over; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Neoplasm Staging; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines | 2017 |
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2018 |
Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Bronchial Neoplasms; Carcinoid Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Protein Kinase Inhibitors | 2018 |
Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Neoplasms, Unknown Primary; Protein Kinase Inhibitors | 2018 |
Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adrenal Cortex Hormones; Anaplastic Lymphoma Kinase; Carbazoles; Cough; ErbB Receptors; Erlotinib Hydrochloride; Female; Fever; Humans; Hypoxia; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2018 |
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Gene Expression Profiling; Heterografts; Histones; Humans; Immunoblotting; Lung Neoplasms; Mice; Mutant Proteins; Neoplasm Transplantation; Phosphoglycerate Dehydrogenase; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, RNA; Staining and Labeling; Treatment Outcome | 2018 |
Resistant to Targeted Therapy - Aim for Metabolic Liabilities.
Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Phosphoglycerate Dehydrogenase | 2018 |
Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors | 2018 |
Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment.
Topics: Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors | 2018 |
A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation.
Topics: Acrylamides; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Piperazines; Positron Emission Tomography Computed Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Afatinib restrains K-RAS-driven lung tumorigenesis.
Topics: Adenocarcinoma of Lung; Afatinib; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2018 |
USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Proteolysis; Thiolester Hydrolases; Ubiquitin Thiolesterase | 2018 |
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Topics: Adenocarcinoma of Lung; Afatinib; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2018 |
An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Piperazines; Treatment Outcome | 2018 |
Cisplatin Effects in Lung Adenocarcinoma-bearing Mice, Alone and in Combination with Erlotinib.
Topics: Acute Kidney Injury; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Erlotinib Hydrochloride; Mice; Mice, Transgenic | 2018 |
EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Survival Analysis; Young Adult | 2018 |
Iatrogenic pneumopericardium in the setting of carcinomatous pericarditis.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Pericarditis; Pneumopericardium; Protein Kinase Inhibitors; Punctures; Radiography; Ventilators, Negative-Pressure | 2018 |
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue.
Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; Cell-Free Nucleic Acids; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Piperazines; Polymorphism, Restriction Fragment Length | 2018 |
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2019 |
Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Tumor Suppressor Protein p53 | 2018 |
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study.
Topics: Adenocarcinoma of Lung; Adult; Aged; Asian People; Brain Neoplasms; China; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis | 2018 |
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs).
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Retrospective Studies; Tomography, X-Ray Computed | 2018 |
Erlotinib-Associated Rash Exacerbated by Whole-Brain Radiation Therapy: A Patient's Case Report.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Face; Female; Humans; Lung Neoplasms; Radiodermatitis; Skin; Treatment Outcome | 2019 |
Next-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Leptomeningeal Carcinomatosis: Review of 2 Cases.
Topics: Adenocarcinoma of Lung; Afatinib; Aged; Brain; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Integrin beta1; Lung Neoplasms; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; rab GTP-Binding Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2019 |
FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cohort Studies; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Staging; Piperazines; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 4; Respiratory Mucosa; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2019 |
Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Cell Growth Processes; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Mutation; Precision Medicine | 2019 |
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.
Topics: Acrylamides; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Animals; CHO Cells; Cricetulus; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Humans; Models, Chemical; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Heart Transplantation; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Mutation | 2019 |
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines | 2013 |
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2013 |
[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Salvage Therapy | 2013 |
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platform
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; False Positive Reactions; Gefitinib; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2014 |
[Assessing the usefulness of erlotinib in patients with unknown or negative epidermal growth factor receptor mutation status].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2014 |
[Radiosensitizing effect of erlotinib on human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Particle Accelerators; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2013 |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Phosphatidylinositol 3-Kinases; Precision Medicine; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2014 |
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2014 |
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Case of erlotinib-induced photosensitivity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Dermatitis, Photoallergic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Patch Tests; Protein Kinase Inhibitors; Quinazolines | 2014 |
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2014 |
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Tandem Mass Spectrometry | 2015 |
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Interleukin-6; Janus Kinase 1; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, SCID; Mutation; Nitriles; Oncogenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; ras Proteins; Receptors, Fibroblast Growth Factor; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Intensive Care Units; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Respiration, Artificial; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cohort Studies; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis | 2014 |
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Outcome | 2014 |
Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pakistan; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction | 2014 |
Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Animals; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Heparin-binding EGF-like Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Matrix Metalloproteinase 1; Mice, Nude; Middle Aged; Neoplasm Staging; Neuregulin-1; Neurotensin; Paracrine Communication; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Cysts; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Pneumothorax; Protein Kinase Inhibitors; Quinazolines; Rupture, Spontaneous | 2014 |
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms; Mass Spectrometry; Phosphopeptides; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2015 |
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Molecular; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2015 |
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2015 |
Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; Treatment Outcome | 2015 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
Remission of advanced EGFR-positive lung adenocarcinoma after short and intermittent erlotinib therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antimetabolites, Antineoplastic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors | 2015 |
Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrosis, Lipoid; Protein Kinase Inhibitors; Quinazolines | 2015 |
Erlotinib enhances the CIK cell-killing sensitivity of lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Combined Modality Therapy; Cytokine-Induced Killer Cells; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; NK Cell Lectin-Like Receptor Subfamily K | 2015 |
Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomechanical Phenomena; Cell Line, Tumor; Collagen Type I; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Fibrosis; Humans; Indoles; Integrins; Lung; Lung Neoplasms; Mechanotransduction, Cellular; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Sulfones | 2015 |
Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cost-Benefit Analysis; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Germany; Humans; Lung Neoplasms; Models, Economic; Mutation; Neoplasm Invasiveness; Precision Medicine; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2015 |
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Treatment Outcome | 2015 |
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Quinazolinones; Signal Transduction; Up-Regulation | 2015 |
Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Live Birth; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy, Twin; Protein Kinase Inhibitors; Treatment Outcome | 2015 |
Erlotinib-related keratopathy in a patient underwent laser in situ keratomileusis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Bone Neoplasms; Corneal Diseases; ErbB Receptors; Erlotinib Hydrochloride; Humans; Keratomileusis, Laser In Situ; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Spinal Neoplasms | 2016 |
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cetuximab; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines | 2016 |
An Autopsy Case of Two Distinct, Acquired Drug Resistance Mechanisms in Epidermal Growth Factor Receptor-mutant Lung Adenocarcinoma: Small Cell Carcinoma Transformation and Epidermal Growth Factor Receptor T790M Mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autopsy; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Deletion; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation | 2015 |
Effects of kinase insert domain receptor (KDR) gene silencing on the sensitivity of A549 cells to erlotinib.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Silencing; Humans; Lung Neoplasms; RNA, Messenger; RNA, Small Interfering; Tetrazolium Salts; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
[Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Treatment Outcome | 2016 |
Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mutation; Treatment Outcome | 2016 |
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolinones; Random Allocation; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2016 |
Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biological Assay; Cell Proliferation; DNA Mutational Analysis; Erlotinib Hydrochloride; Exome; Female; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Metabolic Networks and Pathways; Models, Biological; Mutation; Pleural Effusion, Malignant; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
The impact of autophagy on cell death modalities in CRL-5876 lung adenocarcinoma cells after their exposure to γ-rays and/or erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Chloroquine; DNA Breaks, Double-Stranded; DNA Repair; Erlotinib Hydrochloride; Gamma Rays; Humans; Lung Neoplasms | 2016 |
Efficacy of erlotinib and imatinib in a patient with a rectal gastrointestinal stromal tumor and synchronous pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Genes, erbB-1; Humans; Imatinib Mesylate; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms, Multiple Primary; Proto-Oncogene Proteins c-kit; Rectal Neoplasms | 2016 |
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; AMP-Activated Protein Kinases; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Interaction Maps; Protein Kinase Inhibitors; Signal Transduction | 2016 |
Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Smoking; Survival Analysis | 2016 |
Hepatoid adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Staging; Pneumonia; Tomography, X-Ray Computed | 2016 |
Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Trees; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Health Care Costs; Humans; Lung Neoplasms; Male; Markov Chains; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Precision Medicine; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Republic of Korea | 2016 |
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2016 |
Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Biopsy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Translocation, Genetic | 2017 |
Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Mass Spectrometry; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Precision Medicine; Protein Interaction Mapping; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor, ErbB-2; White People | 2016 |
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anilides; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Treatment Outcome | 2016 |
Targeted therapy of multiple liver metastases after resected solitary gastric metastasis and primary pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gastrectomy; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Positron Emission Tomography Computed Tomography; Stomach Neoplasms | 2016 |
Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Reply to C.-H. Chang et al.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans | 2017 |
Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior?
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2017 |
Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Treatment Failure | 2017 |
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Movement; Cell Proliferation; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2017 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Failure | 2011 |
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; bcl-X Protein; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mice; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Transplantation, Heterologous | 2011 |
Papulopustular eruptions in a 32-year-old woman after lung cancer treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Metronidazole; Mupirocin; Quinazolines | 2011 |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA | 2012 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Middle Aged; Molecular Sequence Data; Neuroendocrine Cells; Nuclear Proteins; Proteins; Proteome; Proteomics; Quinazolines; RNA Interference; RNA, Small Interfering; Small Cell Lung Carcinoma; Thyroid Nuclear Factor 1; Transcription Factors | 2011 |
EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoembryonic Antigen; Drainage; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleura; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tissue Polypeptide Antigen; Treatment Outcome | 2012 |
[Efficacy of combination therapy with EGFR-TKI and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKI].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2012 |
A case of choroidal metastasis of lung cancer successfully treated with erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Choroid Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines | 2012 |
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Mutation; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2012 |
Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multimodal Imaging; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[Carcinomatous meningitis in a post-operative patient with lung adenocarcinoma for which erlotinib was effective - a case report].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Membrane Potentials; Patch-Clamp Techniques; Phlorhizin; Protein-Tyrosine Kinases; Quinazolines; Radiation Dosage; Sodium-Glucose Transport Proteins; Tumor Cells, Cultured | 2012 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt | 2012 |
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction; Transcription, Genetic; Trifluoperazine; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Genes, erbB-1; Humans; Janus Kinase 2; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Rate | 2012 |
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease-Free Survival; Ephrins; Epithelial Cells; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multivariate Analysis; Mutation, Missense; Neoplasm Invasiveness; Occludin; Proportional Hazards Models; Quinazolines; Receptor, EphA4 | 2012 |
Fatal asymmetric interstitial lung disease after erlotinib for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Failure; Vinblastine; Vinorelbine | 2012 |
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering | 2012 |
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Transcription Factors | 2012 |
Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |